NASDAQ:IMMX Immix Biopharma Q3 2026 Earnings Results & Report $7.95 -0.12 (-1.50%) As of 11:30 AM Eastern This is a fair market value price provided by Massive. Learn more. Immix Biopharma missed analyst earnings expectations in its Q3 2026 results, released November 12, 2026. The company reported EPS of -$0.19 versus the -$0.18 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 12, 2026TimeAfter Market ClosesConference Call7:00 AM ET Immix Biopharma EPS ResultsActual EPS-$0.19Consensus EPS -$0.18Beat/MissMissed by -$0.01One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersImmix Biopharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Immix Biopharma Q3 2026 Earnings FAQ Did Immix Biopharma beat earnings estimates for Q3 2026? Immix Biopharma (NASDAQ:IMMX) reported earnings of -$0.19 per share for Q3 2026, missing the consensus estimate of -$0.18. The report was announced on Thursday, November 12, 2026. Immix Biopharma Earnings HeadlinesImmix Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 12 at 11:32 PM | marketscreener.comMImmix Biopharma Reports Positive NEXICART-2 Data, Advances Commercial Readiness and Third Quarter 2026 Financial ResultsNovember 12 at 4:31 PM | quiverquant.comQUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 13 at 1:00 AM | Digest Publishing (Ad)Immix Biopharma Reports Third Quarter 2026 Financial Results and Update on Corporate ProgressNovember 12 at 4:15 PM | globenewswire.comImmix Biopharma’s NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026November 4, 2026 | markets.businessinsider.comImmix Biopharma's NXC-201 NEXICART-2 Interim Clinical Trial Results Selected for Oral Presentation at ASH 2026November 4, 2026 | globenewswire.comSee More Immix Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Immix Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immix Biopharma and other key companies, straight to your email. Email Address About Immix BiopharmaImmix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues.The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use.Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.View Immix Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco's Record $30 Dividend Shows Just How Strong Its Cash Machine IsThese 3 Stocks Have Bought Back Billions, But Which Offers the Best Value?Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went ShoppingGolden Dome’s $185 Billion Question: Who Actually Gets Paid?3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record Growth Upcoming Earnings Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
